EUVIMEDEUVIMED entdecken
Crossref

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies

Mohamed Abdellatif

International Journal of Clinical Pharmacy and Medicine · 01.07.2026 · 1 (1)

DOI: 10.68760/ijcpm.2026.07 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy and Medicine, online erschienen am 01.07.2026. Verfasst von Mohamed Abdellatif.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Abdellatif, M. (2026). SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies. International Journal of Clinical Pharmacy and Medicine, 1(1). https://doi.org/10.68760/ijcpm.2026.07

Vancouver

Abdellatif M. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies. International Journal of Clinical Pharmacy and Medicine. 2026;1(1). doi:10.68760/ijcpm.2026.07

BibTeX
@article{Abdellatif2026,
  author = {Abdellatif, Mohamed},
  title = {SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiorenal-Metabolic Syndrome: Canadian Evidence, Mechanistic Complementarity, and Pharmacotherapeutic Strategies},
  journal = {International Journal of Clinical Pharmacy and Medicine},
  year = {2026},
  volume = {1},
  number = {1},
  doi = {10.68760/ijcpm.2026.07}
}
Kostenlos starten →